Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Visage Imaging Debuts AI Offerings at Chicago Show

By HospiMedica International staff writers
Posted on 27 Nov 2017
Visage Imaging, Inc. More...
(Richmond, VIC, Australia) debuted its artificial intelligence (AI) offerings at the Radiological Society of North America (RSNA) 2017 annual meeting as part of the inaugural RSNA Machine Learning Showcase (November 26-30, Chicago, Illinois).

Visage aims to utilize its R&D capability and market leading technology to deliver cutting-edge AI offerings to optimize Enterprise Imaging worldwide. At RSNA 2017, the company showcased Visage 7 and the technology, which makes it the first and only system to combine both AI research and AI-assisted diagnostic interpretation in the same Enterprise Imaging platform.

“Historically, imaging platforms for research and diagnostic purposes have been totally separate. Visage’s GPU-based architecture is ideal for AI and, combined with our open APIs, will enable us to unify research and diagnostic imaging in ways not available before,” said Malte Westerhoff, PhD, co-founder and global CTO of Visage Imaging. “This will enable AI breakthroughs to advance patient care by giving radiologists faster access to new tools that help increase productivity and improve clinical accuracy.”

The company will also show algorithms working on the ultrafast and highly scalable Visage 7 Enterprise Imaging Platform. Both internally developed algorithms as well as third party algorithms from academic institutions and other companies will be demonstrated.

“AI is evolving rapidly and has the potential to transform Enterprise Imaging in ways previously not imagined,” said Dr. Sam Hupert, CEO of Visage Imaging. “We are well placed to capitalize on this transformation as we look to leverage our three key assets, namely our R&D capability, our technology platform and our growing base of blue chip clients.”

The company’s first AI innovations for Visage 7 are works-in-progress and are scheduled to be released in the first half of 2018.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.